NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis $11.91 -0.01 (-0.08%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$11.61▼$11.9650-Day Range$5.25▼$11.9252-Week Range$4.05▼$12.38Volume33,692 shsAverage Volume179,918 shsMarket Capitalization$326.57 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ClearPoint Neuro alerts: Email Address ClearPoint Neuro MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside19.6% Downside$9.50 Price TargetShort InterestHealthy2.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.46Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.66) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 starsMedical Sector842nd out of 924 stocksSurgical & Medical Instruments Industry91st out of 97 stocks 1.5 Analyst's Opinion Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days.Read more about ClearPoint Neuro's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.94% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLPT. Previous Next 3.6 News and Social Media Coverage News SentimentClearPoint Neuro has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ClearPoint Neuro this week, compared to 1 article on an average week.Search Interest5 people have searched for CLPT on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.11% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions.Read more about ClearPoint Neuro's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.66) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -14.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -14.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 13.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ClearPoint Neuro's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About ClearPoint Neuro Stock (NASDAQ:CLPT)ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Read More CLPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLPT Stock News HeadlinesAugust 19 at 1:54 AM | americanbankingnews.comShort Interest in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Drops By 5.9%August 13, 2024 | americanbankingnews.comQ3 2024 Earnings Estimate for ClearPoint Neuro, Inc. (NASDAQ:CLPT) Issued By B. RileyAugust 22, 2024 | TradingTips (Ad)Buy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.August 9, 2024 | seekingalpha.comClearPoint Neuro: My Favorite Growth StockAugust 9, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comClearPoint Neuro, Inc. (CLPT) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | uk.finance.yahoo.comClearPoint Neuro Reports Second Quarter 2024 ResultsAugust 7, 2024 | markets.businessinsider.comHere's what to expect from ClearPoint Neuro's earningsAugust 22, 2024 | TradingTips (Ad)Buy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.July 27, 2024 | investorplace.comThe 3 Best Brain-Computer Interface Stocks to Buy NowJuly 17, 2024 | globenewswire.comClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024July 17, 2024 | investorplace.com7 Growth Stocks That Could 5X in 5 YearsJune 20, 2024 | globenewswire.comClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical TrialJune 20, 2024 | prnewswire.comParkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement NeuronsJune 1, 2024 | globenewswire.comClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy SystemMay 8, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comClearPoint Neuro Inc (CLPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth ...May 7, 2024 | finance.yahoo.comClearPoint Neuro Inc. Reports Strong Q1 2024 Performance, Surpassing Revenue ExpectationsSee More Headlines Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLPT CUSIPN/A CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$10.00 Low Stock Price Target$9.00 Potential Upside/Downside-19.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,090,000.00 Net Margins-78.84% Pretax Margin-78.84% Return on Equity-76.92% Return on Assets-43.94% Debt Debt-to-Equity RatioN/A Current Ratio3.14 Quick Ratio2.61 Sales & Book Value Annual Sales$28.07 million Price / Sales11.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book13.73Miscellaneous Outstanding Shares27,420,000Free Float25,745,000Market Cap$323.83 million OptionableOptionable Beta1.07 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Joseph Michael Burnett (Age 47)President, CEO & Director Comp: $803.12kMr. Danilo D'Alessandro (Age 38)Chief Financial Officer Comp: $459.26kMr. Jeremy Stigall (Age 40)Chief Business Officer Comp: $392.66kMr. Mazin Sabra (Age 43)Chief Operating Officer Ms. Ellisa CholapraneeGeneral Counsel & SecretaryMs. Jacqueline KellerVice President of MarketingMore ExecutivesKey CompetitorsPro-DexNASDAQ:PDEXT2 BiosystemsNASDAQ:TTOOApyx MedicalNASDAQ:APYXiCADNASDAQ:ICADNeuroneticsNASDAQ:STIMView All CompetitorsInstitutional OwnershipPoint72 Asia Singapore Pte. Ltd.Bought 32,424 shares on 8/15/2024Ownership: 0.118%Squarepoint Ops LLCBought 101,773 shares on 8/14/2024Ownership: 0.371%Cubist Systematic Strategies LLCBought 77,750 shares on 8/14/2024Ownership: 0.284%Marshall Wace LLPBought 38,984 shares on 8/14/2024Ownership: 0.212%Point72 DIFC LtdBought 6,010 shares on 8/14/2024Ownership: 0.022%View All Institutional Transactions CLPT Stock Analysis - Frequently Asked Questions How have CLPT shares performed this year? ClearPoint Neuro's stock was trading at $6.79 on January 1st, 2024. Since then, CLPT shares have increased by 73.9% and is now trading at $11.81. View the best growth stocks for 2024 here. How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) posted its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The company earned $7.86 million during the quarter, compared to analysts' expectations of $7.50 million. ClearPoint Neuro had a negative trailing twelve-month return on equity of 76.92% and a negative net margin of 78.84%. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's top institutional shareholders include Renaissance Technologies LLC (0.62%), Legato Capital Management LLC (0.58%), Squarepoint Ops LLC (0.37%) and Cubist Systematic Strategies LLC (0.28%). View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLPT) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
